Designed with our AI-Immunology™ platform, EVX-01 and is tailored to target the unique tumor profile and immune characteristics of each patient. It engages the patient's immune system to fight off ...

Macrophages, key regulators of tissue health and immune defense, are among the most abundant immune cells in solid tumors. Their role in cancer has been difficult to define because even closely ...

The advent of single-cell omics technologies has revolutionized our understanding of the complex cellular landscape in cancer. Traditional bulk sequencing ...

Cancer immunology is advancing rapidly as researchers seek to unravel the complex, dynamic relationships between tumor cells, immune populations, and the ...

A new study published in The Journal of Immunology by researchers at the Josep Carreras Leukaemia Research Institute (IJC) ...

About Evaxion Evaxion is a pioneering TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. The platform harnesses the power of artificial ...

The intersection of cancer immunology and immunoglobulin expression has emerged as a dynamic field, challenging traditional views on immune responses and tumour biology. Research has demonstrated that ...

Newest version of BD® Research Cloud features an AI-powered tool for automated panel design to improve quality, efficiency and usability of scientific results across research areas FRANKLIN LAKES, N.J ...

Cancer affects millions of individuals and their loved ones each year. Both hematologic or blood cancers, and solid tumors can have fatal outcomes. Fortunately, the advancement of medicine and ...

The American Association for Cancer Research (AACR) will present the 2026 AACR Award for Lifetime Achievement in Cancer Research to James P. Allison, PhD, Fellow of the AACR Academy, during the AACR ...

The Cancer Research Institute (CRI), a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, will bestow its highest honors on three ...

Biocon Ltd has received approval from Health Canada for its biosimilars, Bosaya and Vevzuo, intended for treating osteoporosis and cancer-related bone complications. This approval underscores Biocon's ...